Drugs / [18F]FluorThanatrace
[18F]FluorThanatrace
also known as
18F-FTT · 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo\[cd\]azulen-6(7H)-one · FTT
Diagnostic / imaging agent targets PARP1 via inhibition
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT05636540 | Jul 2023 → Dec 2026 expected | paraganglioma, pheochromocytoma | Heather Wachtel | Recruiting | No outcome recorded |
| Phase 0 | NCT04221061 | Feb 2020 → Jun 2024 | glioblastoma | University of Pennsylvania | Terminated | No outcome recorded |
| Phase 0 | NCT03334500 | Jul 2017 → Feb 2027 expected | prostate cancer | Abramson Cancer Center at Penn Medicine | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02469129 | Mar 2015 → Jul 2024 | cancer | Washington University School of Medicine | Unknown | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT07114939 | Oct 2025 → Sep 2027 expected | neuroendocrine carcinoma, pancreatic neuroendocrine tumor | Abramson Cancer Center at Penn Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT03083288 | Feb 2017 → Jul 2027 expected | breast cancer | Abramson Cancer Center at Penn Medicine | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02637934 | Jan 2016 → Oct 2026 expected | female reproductive system neoplasm | Abramson Cancer Center at Penn Medicine | Recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]Fluorthanatrace | “Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT” NCT02637934 ↗7“[18F]FluorThanatrace” NCT03334500 ↗ |
| Known as | 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo\[cd\]azulen-6(7H)-one | “Investigators at Penn have developed 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo\[cd\]azulen-6(7H)-one, also known as \[18F\]FluorThanatrace or \[18F\]FTT,...” NCT07114939 ↗ |
| Known as | 18F-FTT | “BACKGROUND[18F]FluorThanatrace ([18F]FTT) is a radiolabeled poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi)” PMID 33884961 ↗ Apr 20211“[18F]FluorThanatrace ([18F]FTT)” NCT05636540 ↗ |
| Known as | FTT | “Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT” NCT02637934 ↗ |
| Action | Inhibit | “selective PARP-1 inhibitor” NCT07114939 ↗ |
| Modality | Diagnostic / imaging agent | “A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.” PMID 29509546 ↗ Apr 2018 |
| Route | Intravenous | “will be injected intravenously” NCT02469129 ↗ |
| Target | PARP1 | “uptake of our compound is specific for PARP1 activity” NCT02469129 ↗ |